Clinical trials: CYP19
Endocrine Responsive Early Breast Cancer
Impact of Adjuvant Treatment With Aromatase Inhibitor on Sleep Disturbances in Postmenopausal Women With Endocrine Responsive Early Breast Cancer
Insomnia is common in Breast cancer patients during adjuvant therapy with aromatase inhibitor. However it is difficult to establish whether it is due to the knowledge of the disease or the treatment administred.
- Trial name
- NCT02166281
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Breast Cancer
Clinical Application of Vagus Nerve Stimulation Combined With Immunoregulatory T Cells in Alleviating Aromatase Inhibitor-Induced Pain
The goal of this clinical trial is to learn whether transcutaneous auricular vagus nerve stimulation, also called taVNS, can help relieve aromatase inhibitor-related joint and muscle pain in adult women with hormone…
- Conditions
- Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Breast Cancer, Pain Alleviation
- Trial name
- NCT07593365
- Testing
- transcutaneous auricular vagus nerve stimulation
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Peking University People's Hospital
Breast Cancer
Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients
Aromatase inhibitors are commonly prescribed for treatment of postmenopausal women with breast cancer. These medications can cause side effects in some women, and occasionally they can be quite bothersome.
- Trial name
- NCT01983995
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Michigan
Breast Neoplasms
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
This is a prospective, single-arm, phase II study of 32 evaluable patients treated with NEOADjuvant Aromatase inhibitor and Pertuzumab/Trastuzumab (NEOADAPT) without chemotherapy for hormone receptor positive (HR+), [i.e.
- Trial name
- NEOADAPT (NCT02689921)
- Testing
- Exemestane, Letrozole, Anastrozole
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Midwestern Regional Medical Center
Hypogonadism, Severe Obesity
Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)
After the age of 40, there is a gradual decline in the production of testosterone. Among obese men, the decline in testosterone levels is exacerbated by the suppression of the hypothalamic-pituitary-gonadal axis by…
- Trial name
- NCT02959853
- Testing
- Anastrazole, weight loss
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Hot Flashes, Breast Cancer
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
Hot flashes present a considerable problem for many breast cancer patients; these symptoms may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen.
- Trial name
- NCT01530373
- Testing
- solifenacin, Clonidine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Arkansas
Metastatic Breast Cancer
Overcoming Endocrine Resistance in Metastatic Breast Cancer
Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front-line, switching or extending) and/or as first-line…
- Trial name
- OVER (NCT02394496)
- Testing
- Fulvestrant, Lapatinib, Aromatase Inhibitors
- Where
- 69 sites in Italy
- Volunteers
- 396 people
- Sponsor
- Consorzio Oncotech
Breast Cancer, Breast Cancer Metastatic
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)
This study evalues the efficacy -as determined by the clinical benefit rate (CBR)- of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring…
- Trial name
- LUZERN (NCT04240106)
- Testing
- Niraparib, Aromatase Inhibitors
- Where
- 10 sites in Spain
- Volunteers
- 14 people
- Sponsor
- MedSIR
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Breast Cancer
500mg Fulvestrant Versus Exemestane in MBC
500mg Fulvestrant versus Exemestane in MBC
- Trial name
- NCT03575260
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Breast Cancer
Fasting-mimicking Diet Intervention on Side Effects of Aromatase Inhibitors Treatment in Patients With Breast Cancer
The primary endpoint of this study is to determine whether cycles of short term FMD exposure to a fasting-mimicking diet is effective in reducing total cholesterol levels.
- Trial name
- NCT06610565
- Testing
- FASTING-MIMICKING DIET PROGRAM
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- European Institute of Oncology
Breast Cancer, Breast Carcinoma
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
The purpose of this clinical study is to describe the patient population, breast cancer treatment, and breast cancer treatment results of adult female patients who have received palbociclib combination treatments for advanced or…
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Neoplasms, Breast Tumors
- Trial name
- NCT05584644
- Testing
- Palbociclib plus hormonal treatment - first line treatment, Palbociclib plus hormonal treatment - second line treatment
- Where
- 6 sites in India
- Volunteers
- 150 people
- Sponsor
- Pfizer
Musculoskeletal Pain
Targeted Physiotherapeutic Treatment for Aromatase Inhibitor-associated Musculoskeletal Pain in Breast Cancer Survivors
The primary objective of this trial is to assess the efficacy of targeted individualised physiotherapeutic treatment on aromatase inhibitor-associated musculoskeletal pain.
- Trial name
- AIMSS (NCT04560699)
- Testing
- Physiotherapeutic treatment and medical care, medical care
- Where
- Denmark
- Volunteers
- 111 people
- Sponsor
- Frederiksberg University Hospital
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
This clinical trial evaluates if in-person acupuncture or virtual acupressure therapy prevents aromatase inhibitor-associated joint pain in Non-Hispanic Black postmenopausal women with stage I-III (early-stage) hormone receptor…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
- Trial name
- NCT06534125
- Testing
- Acupressure Therapy, Acupuncture Therapy, Aromatase Inhibition Therapy
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- Emory University
Vasomotor Symptoms (VMS)
Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.
- Trial name
- NCT04080297
- Testing
- oral capsule of Q-122
- Volunteers
- 21 people
- Sponsor
- Que Oncology
Advanced Breast Cancer
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
The purpose of this study is to find out what effect the combination of fulvestrant (Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant alone.
- Trial name
- NCT00754325
- Testing
- Dasatinib, Fulvestrant
- Where
- 28 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
To determine whether treatment with alpelisib plus fulvestrant prolonged progression-free survival (PFS) compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), human epidermal…
- Trial name
- SOLAR-1 (NCT02437318)
- Testing
- Fulvestrant, Alpelisib
- Where
- 197 sites in United States, Argentina and 29 more
- Volunteers
- 572 people
- Sponsor
- Novartis Pharmaceuticals
Early Breast Cancer
Activity Program During Aromatase Inhibitor Therapy
The primary aim of the trial is to investigate if a simple outdoor walking intervention, which is practicable under real-life conditions, beginning at the start of adjuvant aromatase inhibitor (AI) therapy, can prevent the…
- Trial name
- NCT03786198
- Testing
- Activity program, Control
- Where
- 32 sites in Switzerland
- Volunteers
- 375 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00423917
- Testing
- bevacizumab, fulvestrant
- Where
- 205 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Medication Adherence
Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors
The proposed research is a randomized controlled investigation of the efficacy of motivational interviewing (MI) to improve adherence to aromatase inhibitors (AI) in a community sample of patients with poor adherence to AIs.
- Trial name
- MI for AIs (NCT02883361)
- Testing
- Motivational enhancement therapy, Attention Control
- Where
- Canada
- Sponsor
- University of Calgary